

March 17, 2022

**BSE Limited**Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E), Mumbai - 400 051

Dear Sirs,

We enclose a communication pertaining to USFDA approval.

This is for your information and records.

Thanking you,

Yours faithfully, For Jubilant Pharmova Limited

Rajiv Shah Company Secretary

Encl.: as above

**A Jubilant Bhartia Company** 



Jubilant Pharmova Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel: +91 120 4361000 Fax: +91 120 4234895-96 www.jubilantpharmova.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223 UP, India

CIN: L24116UP1978PLC004624



## Jubilant receives ANDA approval for Doxepin Hydrochloride Capsules

## Noida (UP), India, Thursday, March 17, 2022

Jubilant Pharmova Limited, an integrated global Pharmaceuticals Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its subsidiaries, Jubilant Cadista Pharmaceuticals Inc. has received Abbreviated New Drug Application (ANDA) final approval for **Doxepin Hydrochloride Capsules**, 10 mg, 25mg, 50mg, 75mg, and 100mg, the generic version of Sinequan®, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis.

As on December 31, 2021, Jubilant's Pharmaceuticals business had a total of 98 ANDAs for Oral Solids filed in the US, of which 61 have been approved and 4 Injectable/Opthalmic filings, of which 2 have been approved.

## **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

## For more information, please contact:

For Investors **Vineet V Mayer**Ph: +91 120 436 1103

E-mail: vineet.mayer@jubl.com

Siddharth Rangnekar |Karl Kolah CDR India Ph: +91 97699 19966 / 9833010478

E-mail: siddharth@cdr-india.com karl@cdr-india.com